These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 9124828

  • 1. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
    Blanche F, Cameron B, Bernard FX, Maton L, Manse B, Ferrero L, Ratet N, Lecoq C, Goniot A, Bisch D, Crouzet J.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
    [Abstract] [Full Text] [Related]

  • 2. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
    [Abstract] [Full Text] [Related]

  • 3. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 4. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F.
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [Abstract] [Full Text] [Related]

  • 5. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
    Fernandez-Moreira E, Balas D, Gonzalez I, de la Campa AG.
    Microb Drug Resist; 2000 Aug; 6(4):259-67. PubMed ID: 11272253
    [Abstract] [Full Text] [Related]

  • 6. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY, Trucksis M, Hooper DC.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [Abstract] [Full Text] [Related]

  • 7. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B, Hooper DC.
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.
    Tanaka M, Onodera Y, Uchida Y, Sato K, Hayakawa I.
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2362-6. PubMed ID: 9371334
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
    Alt S, Mitchenall LA, Maxwell A, Heide L.
    J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
    [Abstract] [Full Text] [Related]

  • 10. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.
    Saiki AY, Shen LL, Chen CM, Baranowski J, Lerner CG.
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1574-7. PubMed ID: 10390205
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J, Okamoto S, Takahata M, Nishino T.
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [Abstract] [Full Text] [Related]

  • 12. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J, Robicsek A, Hooper DC.
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [Abstract] [Full Text] [Related]

  • 13. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
    Pan XS, Hamlyn PJ, Talens-Visconti R, Alovero FL, Manzo RH, Fisher LM.
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
    [Abstract] [Full Text] [Related]

  • 14. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H, Wiedemann B, Heisig P.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [Abstract] [Full Text] [Related]

  • 15. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS, Fisher LM.
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [Abstract] [Full Text] [Related]

  • 16. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
    Morrissey I, George J.
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
    [Abstract] [Full Text] [Related]

  • 17. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N.
    Biochemistry; 2000 Mar 14; 39(10):2726-32. PubMed ID: 10704224
    [Abstract] [Full Text] [Related]

  • 18. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
    Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Lückefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Köhrer K, Jones ME.
    J Antimicrob Chemother; 1998 Apr 14; 41(4):481-4. PubMed ID: 9598779
    [Abstract] [Full Text] [Related]

  • 19. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ.
    Antimicrob Agents Chemother; 2007 Jul 14; 51(7):2445-53. PubMed ID: 17502409
    [Abstract] [Full Text] [Related]

  • 20. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.
    Hoshino K, Kitamura A, Morrissey I, Sato K, Kato J, Ikeda H.
    Antimicrob Agents Chemother; 1994 Nov 14; 38(11):2623-7. PubMed ID: 7872758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.